内容制作
温馨提示:本文仅基于疾病科普分享,不能代替医院诊疗。意见仅供参考,具体治疗方式请遵医嘱。
封面图片:觅健
责任编辑:觅健科普君
参考资料:
[1]国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组.肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J].中国实用外科杂志,2021,41(1):20-30.
[2]国家卫健委.原发性肝癌诊疗指南(2022年版).临床肝胆病杂志,2022,38(2):306-321.
[3]WANG Z, REN Z, CHEN Y, et al. Adjuvant transarterial chemoembolization for HBV-relact hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Canca Res, 2018, 24 (9): 2074-2081.
[4]潘扬勋,陈敏山,徐立.经肝动脉灌注化疗在肝癌围术期的作用[J].肝胆胰外科杂志,2022,34(07):389-393.
[5]KUDO M. Adjuvant nivolumab for hepatocellular carcinoma ( HCC) after surgical resection ( SR) or radiofrequency ablation ( RFA) ( NIVOLVE) : A phase 2 prospective multicenter single - arm trial and exploratory biomarker analysis, ASCO Annual Meeting,F,2021[C]. American Society of Clinical Oncology.
[6]Andrew Zhu, Masatoshi Kudo, Arndt Vogel, Thomas Yau, Jian Zhou, Eunhee Kim, Usha Malhotra, Abby B. Siegel, Ann-Lii Cheng. Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT284.
[7]YANG X,SUN H,HU B,et al. 944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellu-lar carcinoma in CNLC II and III stage: A single - center pro-spective phase II trial[J]. Annals Oncol,2021,32: S824.
[8]中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南2022.中国临床肿瘤学会,人民卫生出版社
[9]WANG MD, LIC, LIANG L, et al. Early and late recurrence of hepatitis Bhepstost
lular carcinoma [J]. Oncologist, 2020, 25 (10): e1541-e1551.
[10] YAN WT, LI C, YAO LQ, et al. Predictors and long-term proghosis of early and late recument for patients undergoing hepatic resection of hepatocellular carcinoma: a l
study [J]. Hepatobiliary Surg Nutr, 2022, Published Online.
[11]罗氏公司宣布了 IMbrave050 研究在预设的中期分析中达到了主要研究终点: https://www./news/home/20230118005680/en/Genentech’s-Tecentriq-Plus-Avastin-Is-the-First-Treatment-Combination-to-Reduce-the-Risk-of-Cancer-Returning-in-People-With-Certain-Types-of-Early-Stage-Liver-Cancer-in-a-Phase-III-Trial
[12]Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)Study Record | Beta ClinicalTrials.gov
[13]Ren Z, et al. Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer 2022. Advance online publication. doi: 10.1159/000526638
👇